|Year : 2019 | Volume
| Issue : 1 | Page : 18-28
Traditional Chinese medicine based on Zheng differentiation versus angiotensin receptor blocker/angiotensin-converting enzyme antagonist in efficacy of treating diabetic kidney disease: A meta-analysis of randomized clinical trials
Wei-Jun Huang1, Tao Yang2, Chuan-Jiang Liu2, Yong-Hua Xiao2, Qiang Fu2, Qing Gong2, Hua Zhang2, Fan Shao2, Hong Yue2, Shi-Dong Wang2, Jin-Xi Zhao2
1 Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Beijing, China
2 Second Department of Endocrinology and Nephropathy, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
|Date of Submission||28-Aug-2018|
|Date of Acceptance||18-Oct-2018|
|Date of Web Publication||7-Mar-2019|
Second Department of Endocrinology and Nephropathy, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700
Second Department of Endocrinology and Nephropathy, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700
Source of Support: None, Conflict of Interest: None
Objective: To compare the efficacy of traditional Chinese medicine (TCM) based on Zheng differentiation with angiotensin receptor blocker/angiotensin-converting enzyme inhibitor (ARB/ACEI) in treating diabetic kidney disease (DKD) from the aspects of decreasing urinary microalbumin, declining 24-h urinary protein, reducing endpoint events, and renal function protection. Methods: The Chinese Biomedical Literature Database (CBM), the Chinese Academy of Sciences database (CNKI), the VIP Chinese journal database, Wanfang DATA, Medline database, Cochrane library, excerpt medical database (Embase), and Web of science were used for literature searching. The reviewer manager 5.3 software was utilized to analyze the data. Results: Twenty-four studies including 1956 participants were involved in this review. Results showed that TCM had a better effect (mean difference [MD], −23.20, 95% confidence interval [CI], −30.60 to −15.79, P < 0.00001) than ARB/ACEI on lowering urinary albumin excretion rate (UAER) and urine albumin-to-creatinine ratio (MD −4.56 mg/mmol, 95% CI, −5.76 to −3.36, P < 0.00001). Moreover, the advantage of decreasing UAER was greater as the follow-up period become longer (P = 0.04). TCM also had a better effect in 24-h urinal protein, decreasing 0.36 g/24 h (95% CI, −0.45 to −0.27, P < 0.00001) more than the control in shorter follow-up period (ranged from 12 to 24 weeks) subgroup but only 0.08 g/24 h (95% CI, −0.13 to −0.03, P = 0.0006) in the longer follow-up period (>24 weeks) subgroup. TCM worked as well as ACEI/ARB in reducing endpoint events (relative risk, 0.67, 95% CI, 0.20–2.224, P = 0.51) and decreasing urinary albumin concentration (UAC) (MD, −16.50, 95% CI, −46.28–13.28, P = 0.28). As for protecting renal function, TCM had an equal effect to AECI/ARB in improving creatinine clearance ratio (MD, −3.30, 95% CI, −6.66–0.03, P = 0.05) or estimated glomerular filtration rate (MD, 1.00, 95% CI, −0.59–2.58, P = 0.22). However, TCM had a better effect in releasing the glomerular hyperfiltration state (MD, −9.64, 95% CI, −14.45 to −4.84, P < 0.0001). Conclusions: TCM based on Zheng differentiation can work as well as ACEI/ARB in treating DKD and even better in decreasing urinary microalbumin and releasing glomerular hyperfiltration. It is a good alternative treatment of DKD.
Keywords: Angiotensin receptor antagonists, angiotensin-converting enzyme inhibitors, diabetic kidney disease, meta-analysis, traditional Chinese medicine
|How to cite this article:|
Huang WJ, Yang T, Liu CJ, Xiao YH, Fu Q, Gong Q, Zhang H, Shao F, Yue H, Wang SD, Zhao JX. Traditional Chinese medicine based on Zheng differentiation versus angiotensin receptor blocker/angiotensin-converting enzyme antagonist in efficacy of treating diabetic kidney disease: A meta-analysis of randomized clinical trials. World J Tradit Chin Med 2019;5:18-28
|How to cite this URL:|
Huang WJ, Yang T, Liu CJ, Xiao YH, Fu Q, Gong Q, Zhang H, Shao F, Yue H, Wang SD, Zhao JX. Traditional Chinese medicine based on Zheng differentiation versus angiotensin receptor blocker/angiotensin-converting enzyme antagonist in efficacy of treating diabetic kidney disease: A meta-analysis of randomized clinical trials. World J Tradit Chin Med [serial online] 2019 [cited 2019 Mar 18];5:18-28. Available from: http://www.wjtcm.net/text.asp?2019/5/1/18/253496
| Introduction|| |
Diabetic kidney disease (DKD) is a common microvascular complication of diabetes, which has been the main cause of end-stage renal disease (ESRD). DKD is characterized by the rapid progress. The progressing speed is almost 14 times to other kidney diseases when mass proteinuria appears. Angiotensin-converting enzyme inhibitors and angiotensin II Type 1 receptor blockers (ACEI and ARB) are the only two proved effective treatments for DKD up to now. The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study has proved that losartan could reduce the incidence of a doubling of the serum creatinine concentration (risk reduction, 25%; P = 0.006) and ESRD (risk reduction, 28%; P = 0.002), but had no effect on the rate of death. The IDNT study showed that irbesartan safely and significantly slowed the rate of Δestimated glomerular filtration rate (ΔeGFR) (mean change in eGFR from baseline) decline in patients with established type 2 diabetic nephropathy and CKD Stages 1–5, compared to amlodipine and placebo.
Similar to ARB and ACEI drugs, traditional Chinese medicine (TCM) also has been demonstrated to have positive effect in treating DKD. Our studies showed that TCM therapies have a better effect of protecting the kidney function, delaying the progression of DKD, and reducing the proteinuria.,, However, some studies failed to prove that TCM had a better effect.,, To assess whether TCM has a better effect than ACEI/ARB in treating DKD or not, we performed this meta-analysis. Anti-proteinuria and renoprotective effect were the main points for analyzing. Only randomized clinical trials fulfilling the inclusion criteria were included for analysis.
| Methods|| |
The prospective protocol was registered on the international prospective register of systematic reviews PROSPERO (CRD42017058101). The Preferred Reporting Items for Systematic Review and Meta-Analysis statement was followed when we reported this study.
Four Chinese databases were used to retrieve articles, including the Chinese Biomedical Literature Database (CBM), the Chinese Academy of Sciences database (CNKI), the VIP Chinese journal database, and Wanfang DATA. Meanwhile, articles published in English were retrieved in the Medline database, Cochrane library, excerpt medical database (Embase), and Web of science. The keywords including “Diabetic Nephropathy,” “Chinese Herbal Drugs,” “Traditional Chinese Medicine,” “Angiotensin-Converting Enzyme Inhibitors,” “Angiotensin II Type 1 Receptor Blockers,” and “Randomized Controlled Trial.” Their related free words were also used to retrieve articles. Publication date had no limitation. The search strategy of Medline database is presented as follows:
(“Diabetic Nephropathies” [Mesh] OR “Nephropathies, Diabetic” [Title/Abstract] OR “Nephropathy, Diabetic” [Title/Abstract] OR “Diabetic Nephropathy” [Title/Abstract] OR “Diabetic Kidney Disease” [Title/Abstract] OR “Diabetic Kidney Diseases” [Title/Abstract] OR “Kidney Disease, Diabetic” [Title/Abstract] OR “Kidney Diseases, Diabetic” [Title/Abstract] OR “Diabetic Glomerulosclerosis” [Title/Abstract] OR “Kimmelstiel-Wilson Syndrome” [Title/Abstract] OR “Kimmelstiel Wilson Syndrome” [Title/Abstract] OR “Syndrome, Kimmelstiel-Wilson” [Title/Abstract] OR “Kimmelstiel-Wilson Disease” [Title/Abstract] OR “Kimmelstiel Wilson Disease” [Title/Abstract] OR “Nodular Glomerulosclerosis” [Title/Abstract] OR “Glomerulosclerosis, Nodular” [Title/Abstract] OR “Glomerulosclerosis, Diabetic” [Title/Abstract] OR “Intracapillary Glomerulosclerosis” [Title/Abstract]) AND (“Drugs, Chinese Herbal” [Mesh] OR “Chinese Drugs, Plant” [Title/Abstract] OR “Chinese Herbal Drugs” [Title/Abstract] OR “Herbal Drugs, Chinese” [Title/Abstract] OR “Plant Extracts, Chinese” [Title/Abstract] OR “Chinese Plant Extracts” [Title/Abstract] OR “Extracts, Chinese Plant” [Title/Abstract] OR “Medicine, Chinese Traditional” [MeSH Terms] OR “Traditional Chinese Medicine” [Title/Abstract] OR “Chinese Medicine, Traditional” [Title/Abstract] OR “Chung I Hsueh” [Title/Abstract] OR “Hsueh, Chung I” [Title/Abstract] OR “Zhong Yi Xue” [Title/Abstract] OR “Chinese Traditional Medicine” [Title/Abstract] OR “Traditional Medicine, Chinese: [Title/Abstract]) AND (:Angiotensin-Converting Enzyme Inhibitors” [Mesh] OR “Angiotensin Converting Enzyme Inhibitors” [Title/Abstract] OR “Inhibitors, Kininase II” [Title/Abstract] OR “Kininase II Antagonists” [Title/Abstract] OR “Kininase II Inhibitors” [Title/Abstract] OR “Angiotensin I-Converting Enzyme Inhibitors” [Title/Abstract] OR “Angiotensin I Converting Enzyme Inhibitors” [Title/Abstract] OR “Antagonists, Angiotensin-Converting Enzyme” [Title/Abstract] OR “Antagonists, Angiotensin Converting Enzyme” [Title/Abstract] OR “Antagonists, Kininase II” [Title/Abstract]) OR “Inhibitors, ACE” [Title/Abstract] OR “ACE Inhibitors” [Title/Abstract] OR “Inhibitors, Angiotensin-Converting Enzyme” [Title/Abstract] OR “Enzyme Inhibitors, Angiotensin-Converting” [Title/Abstract] OR “Inhibitors, Angiotensin Converting Enzyme” [Title/Abstract] OR “Angiotensin-Converting Enzyme Antagonists” [Title/Abstract] OR “Angiotensin Converting Enzyme Antagonists” [Title/Abstract] OR “Enzyme Antagonists, Angiotensin-Converting” [Title/Abstract] OR “Angiotensin II Type 1 Receptor Blockers” [Mesh] OR “Angiotensin II Type 1 Receptor Antagonists” [Title/Abstract] OR “Type 1 Angiotensin Receptor Blockers” [Title/Abstract] OR “Angiotensin 2 Type 1 Receptor Antagonists” [Title/Abstract] OR “Angiotensin 2 Type 1 Receptor Antagonists” [Title/Abstract] OR “Type 1 Angiotensin Receptor Antagonists” [Title/Abstract] OR “Selective Angiotensin II Receptor Antagonists” [Title/Abstract] OR “Sartans” [Title/Abstract]) AND (“Randomized Controlled Trial” [Publication Type] OR “Randomized Controlled Trials” [Title/Abstract] OR “Clinical Trials, Randomized” [Title/Abstract] OR “Trials, Randomized Clinical” [Title/Abstract] OR “Controlled Clinical Trials, Randomized” [Title/Abstract]).
The eligibility criteria are as follows: (1) The diagnostic criteria of the type 2 diabetes are from the World Health Organization and the participants of DKD were diagnosed with stage III or stage IV according to Mogensen (1984) staging. (2) Research style is randomized clinical study. (3) The intervention is Chinese herbal medicine and the positive control is ACEI/ARB. (4) The sample size should be no <30. (5) The outcomes should include urinary albumin or urine albumin-to-creatinine ratio (UACR) or 24-h urine albumin or 24-h urine protein or endogenous creatinine clearance ratio (Ccr) or eGFR. However, the exclusion criteria are as follows: (1) Ingredients of Chinese herbal drugs (CHD) are not clear. (2) The research has no syndrome diagnostic criteria. (3) Length of follow-up is <12 weeks.
The data were first extracted by one researcher and then were double-checked by the second researcher. If there was inconformity, the decision would be made after negotiating with the third researcher. We developed a data extraction form based on the Cochrane consumers and communication review group's data extraction template. Data of study ID (made up with the name of first author and year of publication), stage of DKD, age of participants, intervention, control, ingredients of CHD, sample, length of follow-up period, and outcomes were extracted from the reports.
Quality assessment and publication bias
Biases of included literature were evaluated according to the Cochrane Collaboration Network Standard. Biases were assessed via the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Bias evaluation was mainly completed by two researchers, while the ultimate decision was made after consulting the third researcher if dissension existed. The assessment of quality and bias was completed with Review Manager 5.3 (Cochrane Collaboration, Oxford, UK).
Both event (dichotomous) data and continuous data were included in this analysis. Dichotomous data were expressed as relative risk (RRs) with 95% confidence interval (CI). Continuous data were expressed as weighted mean differences (WMD) with 95% CI and an overall WMD was calculated. A fixed-effect model was utilized for meta-analysis when there was no statistically significant heterogeneity between groups (P > 0.05). Otherwise, a random effect model was utilized for the analysis. Subgroup analysis by follow-up period was performed. The Review Manager 5.3 Software was utilized to analyze the data.
| Results|| |
Search results and study characteristic
Flow diagram of articles filtration is shown in [Figure 1]. Two thousand and thirty-six records were identified after database searching. After duplicate screening, 993 records left to the next screening. With the eligibility and exclusion criteria, 969 records had been removed and 24 studies were left in the end. The 24 studies included nine academic dissertations and 15 journal articles. All the studies were published in Chinese and were carried out in China. Among these studies, TCM interventions included ancient classic prescription, experiential prescription, and Chinese patent medicine. One thousand nine hundred and fifty-six participants were involved in this review. Fifteen studies enrolled stage III DKD patients. Three studies enrolled stage IV DKD patients and the other six studies enrolled both stage III and IV DKD patients. All studies were randomized controlled trials. Characteristics of each article are shown in [Table 1].
Bias risk of included records
All these studies were grouped randomly. However, only 10 records ,,,,,,,,,, had clearly stated the method of randomization. The random sequence was generated by statistic software in two studies , and by random number table in the other eight studies.,,,,,,, In case of allocation concealment, only one record  showed the specific method and allocation concealment method of the other 23 studies were unclear. As for the blinding, only three studies ,, were conducted under blinding. Among the three records, two records , clearly described the blinding process and the other one record  only stated that single blinding had been used. Besides, two records , had not reported the incomplete outcome data. Selective reporting was not seen in the 24 records. The risk of bias for each study is summarized in [Figure 2].
|Figure 2: Risk of bias graph: judgments about each risk of bias item presented as percentages across all included studies|
Click here to view
Analysis of the outcomes
Efficacy confrontation on urinary albumin
Nineteen records ,,,,,,,,,,,,,,,, reported the effect of TCM and ACEI/ARB on urinary albumin. Among these studies, some used urinary albumin excretion rate (UAER) to estimate the effect and urinary albumin concentration (UAC) was used in the other studies. Therefore, the 19 records were divided into two groups (UAER group with 16 records ,,,,,,,,,,,,,,, and UAC group with 3 records.,, Each group was meta-analyzed respectively. In one record  of the UAER group, the sample of the UAER subgroup was only 15 (8 participants in treatment group and 7 participants in control group). Therefore, it was excluded out of the subgroup meta-analysis. In the end, there were 15 records left in the UAER group and subgroup analysis was performed by the follow-up period. Shorter follow-up period subgroup (SFP subgroup) had a follow-up period ranged between 12 and 24 weeks, while the longer follow-up period subgroup (LFP sub-group) had a follow-up period of more than 24 weeks. Because of the significant statistical heterogeneity (P < 0.00001, I2 = 77%) [Figure 3]a of SFP subgroup, the sensitivity analysis was conducted. When studies of Wang, 2008 and Zhou, 2009 were removed, heterogeneity largely decreased (I2 value reduced from 77% to 15% and P value changed from <0.00001 to 0.30). However, actually, we had not found significant clinical heterogeneity in these two studies. Therefore, these two studies were still included in the analysis and random effects model was chose to analyze the UAER group. The result showed that experimental group had a better effect (mean difference [MD], −23.20, 95% CI, −30.60 to −15.79, P < 0.00001); [Figure 3]a than control group on lowering UAER. In addition, the absolute value of MD in the LFP sub-group (MD, −31.70, 95% CI, −36.35 to −27.05, P < 0.00001) [Figure 3]a is greater (P = 0.04), [Figure 3]a than the SFP subgroup (MD, −21.47, 95% CI, −30.07 to −12.87, P < 0.00001) [Figure 3]a.
|Figure 3: Forest plots of urinary albumin excretion rate. (a) Forest plots of urinary albumin excretion rate with the scale of ug/min. (b) Forest plots of urinary albumin excretion rate with the scale of mg/l|
Click here to view
The UAC group had three studies. Two studies , showed no significant differences between TCM and ACEI/ARB. However, the other study  demonstrated that TCM had a better effect than the ACEI/ARB. Therefore, we infused the three studies and conducted a meta-analysis. Because of the significant statistical heterogeneity (P < 0.00001, I2 = 96%) [Figure 3]b, the random effects model was used to analyze. The result of meta-analysis showed that there was no significant difference between the experimental group and control group (MD, −16.50, 95% CI, −46.28–13.28, P = 0.28) [Figure 3]b.
Efficacy confrontation on urine albumin-to-creatinine ratio
Two records , reported the effect of TCM and ACEI/ARB on UACR. The follow-up period of one study  was 12 weeks and the other one  was 16 weeks. Both results demonstrated that TCM had a better effect in decreasing UACR. The result of meta-analysis of these two studies also showed that the UACR in experimental group declined more compared with control group (MD, −4.56, 95% CI, −5.76 to −3.36, P < 0.00001); [Figure 4].
Efficacy confrontation on 24-h urinal protein
Eleven records ,,,,,,,,,,, reported the effect of TCM and ACEI/ARB on 24-h urinal protein. In one record, the 24-h urinal protein was only measured in 15 participants (7 participants in treatment group and 8 participants in control group). Therefore, it was excluded and only 10 records were meta-analyzed. Because baselines of three studies ,, had huge differences (<0.5 g/24 h) comparing with the other studies (between 0.5 g/24 h and 2 g/24 h), seven studies were left in the meta-analysis. Besides, subgroup analysis was used in the meta-analysis based on the follow-up period. The result of SFP (12–24 weeks) subgroup showed that experimental group had a better effect in 24 h urinal protein, decreasing 0.36 g/24 h (95% CI, −0.45 to −0.27, P < 0.00001) [Figure 5] more than the control group. As for the LFP (>24 weeks) subgroup, experimental group also had a better effect. However, the decline of 24 h urinal protein was only 0.08 g/24 h (95% CI, −0.13 to −0.03, P = 0.0006) [Figure 5] more than the control group.
Efficacy confrontation on endogenous creatinine clearance ratio and estimated glomerular filtration rate
Among the 24 records, there were four records ,,, showed the efficacy confrontation on Ccr and three records ,, showed confrontation on eGFR.
As for the Ccr group, baselines of Ccr in two studies , were higher than the upper limit of normal (120 mL/min) and the other two records , had baselines which is lower than the normal (80 mL/min). Hence, subgroup analysis was conducted based on the baseline of Ccr. The result of the higher baseline (>12 omL/min) subgroup showed that TCM based on Zheng differentiation was better than ACEI/ARB in the effect of declining the Ccr (MD, −9.64, 95% CI, −14.45 to −4.84, P < 0.0001); [Figure 6]. In the lower baseline (<80 mL/min) subgroup, the result showed that TCM could protect renal function as well as ACEI/ARB (MD, 2.61, 95% CI, −2.04–7.27, P = 0.27) [Figure 7]a.
|Figure 7: (a) and (b) Forest plots of creatinine clearance ratio and estimated glomerular filtration rate|
Click here to view
In the eGFR group, all studies showed that both TCM and ACEI/ARB had beneficial effect on protecting renal function, manifesting as maintaining the eGFR or even improving the eGFR. When meta-analyzing, the result showed that experiment group and control group had no significant difference on eGFR (MD, 1.00, 95% CI, −0.59–2.58, P = 0.22); [Figure 7]b.
Efficacy confrontation on endpoint event
Only two records , reported the effect of TCM and ACEI/ARB on endpoint event. The endpoint event was defined as development from stage III into stage IV (Mogensen stages of diabetic nephropathy). One study  followed participants for 12 weeks and the other one  followed for 24 weeks. Results of both studies showed no difference in the risk of endpoint event between TCM and ARB/ACEI group. After meta-analyzing, result were the same (RR, 0.67, 95% CI, 0.20–2.224, P = 0.51) [Figure 6].
Assessment of publication bias
Publication biases were examined by funnel plot. Considering the small amount of records, only the UAER subgroup was used in the assessment. After analysis, an asymmetrical funnel plot was generated [Figure 8]. It prompted that publication biases might existed.
|Figure 8: Funnel plot of publication bias in the urinary albumin excretion rate subgroup|
Click here to view
| Discussion|| |
Zheng is a distinctive conception of TCM, meaning syndrome or pattern. It is the overall physiological and pathological pattern of the human body in response to a given internal and external condition, which usually is an abstraction of internal disharmony. TCM doctor always diagnoses Zheng with a comprehensive analysis of the clinical symptoms and signs gathered by a practitioner using inspection, auscultation, olfaction, interrogation, and palpation of the pulses. In most cases, TCM doctors give a prescription depending on Zheng and disease patients get. Different patients getting the same disease always are treated by different prescriptions because of their different Zheng. What is more important, effectiveness of the prescription mostly depends on whether it is made basing on the Zheng. To get trials that can really reflect the effectiveness of TCM, only researches that have syndrome diagnostic criteria were included in this review.
As we all know, urinary albumin is an important risk factor for renal failure ,, and is often used to estimate new treatments of DKD., In this review, 19 records reported the effect on urinary albumin of TCM based on Zheng differentiation and ACEI/ARB. Primary meta-analysis showed that Chinese herbal medicine had a good effect on reducing UAER and proteinuria. However, is it better than the ACEI/ARB? In this study, results of UAER subgroup showed that the TCM based on Zheng differentiation was more effective than ACEI/ARB and the advantage enlarged as the follow-up period lengthened. The better effect of TCM was also demonstrated in the UACR subgroup. Although the result of UAC subgroup showed no significant difference between TCM and ARB/ACEI, we could not disaffirm the better effect of TCM, considering the tiny sample of UAC subgroup. These results proved that TCM based on Zheng differentiation was more effective than ACEI/ARB in reducing urinary albumin.
Further, 24-h urinal protein is a usefully outcome to assess the effect of treatment for DKD, especially for the IV stage (Mogensen stages of diabetic nephropathy) patients. Many DKD can develop into nephrotic syndrome and diabetes has become the most common secondary cause of nephrotic syndrome, which is difficult to be healed. Besides, the progressing of DKD always accelerates when large amount of urinal protein appears, which means it will develop into ESRD quickly. Hence, if we could decrease the 24-h urinal protein, the speed toward ESRD would be slowed down. As we all know, ARB/ACEI can decrease proteinuria and reduce the risk of developing into ESRD.,,, Studies have shown that combination therapy with Chinese medicine and ACEI/ARB might have polypharmacological anti-proteinuric and renoprotective effects for the management of DKD. However, which is better when they are used separately? In this study, result showed that TCM might be more effective than ACEI/ARB on the reduction of 24-h urinal protein statistically. However, the advantage is so weak that it has no clinical significance. What's more, result will be more credible if more studies included in this review.
Renal function is what patients and doctors mostly care about. DKD has been the leader cause of ESRD. As we all know, ARB/ACEI has been proved that can slow the speed of renal failure., As well as ARB/ACEI, some decoctions based on Zheng differentiation also been verified to be effective in protecting renal function.,, What is better? In this study, Ccr and eGFR were used to access the effectiveness of renal function protection. Results showed that TCM based on Zheng differentiation had a beneficial effect on eGFR as well as ARB/AECI. While results about Ccr showed that TCM had a better effect than ARB/ACEI at the stage of glomerular hyperfiltration with a Ccr higher than normal, when Ccr was lower than normal, TCM could also work as well as ARB/ACEI in improving or maintaining Ccr.
Results above proved that TCM based on Zheng differentiation had better effect than ARB/ACEI in proteinuria decline and no worse effect in protecting renal function, but what about the effect of reducing endpoint events? The findings of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study and IDNT (the Irbesartan in Diabetic Nephropathy Trial) study demonstrated that both losartan and irbesartan could slow the progress of kidney disease in patients with diabetes. In this study, only two records reported effects of TCM and ACEI/ARB on end point event. The endpoint event was defined as development from stage III into stage IV (Mogensen stages of diabetic nephropathy). From the results of these two studies, we could know that no difference was observed between TCM based on Zheng differentiation and ACEI/ARB in reduction of end point events. The result was the same when they were meta-analyzed. The result confirmed to that of renal function protection subgroup. However, considering the tiny sample and short follow-up period, conclusion cannot be made until more and longer follow-up period randomized studies are conducted.
In addition, our meta-analysis had some limitations. First, all the records were published in Chinese and conducted in China. It was easy to generate a language bias and location bias. Second, some low-quality studies were included. Third, many studies had carried on without blinding measure. Besides, only published studies were included in this review. Hence, high-quality randomized controlled clinical trials with larger sample, longer follow-up period, and standard blinding method should be taken in the future.
Financial support and sponsorship
The study was supported by National Natural Science Foundation of China (No. 81473664): Based on the PI3k/Akt signaling pathway mediated immune injury of diabetic nephropathy “treatment in terms of the wind” mechanism.
Conflicts of interest
There are no conflicts of interest.
| References|| |
KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154.
Society MCGoCD. Expert consensus of diabetic kidney disease prevention. Chin J Diabetes Mellitus 2014;6:792-801.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
Evans M, Bain SC, Hogan S, Bilous RW; Collaborative Study Group Participants. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: Post hoc
analysis of the Irbesartan diabetic nephropathy trial. Nephrol Dial Transplant 2012;27:2255-63.
Song ML, Yang M, Mou X, Zhang LF, Zao JX. Evaluation of curative effects of Chinese medical therapies on renal function and symptoms of renal failure of diabetic nephropathy. Beijing Zhong Yi Yao Da Xue Xue Bao 2006;29:429-32.
Jia M, Zhao JX, Dong C, Feng R, Wu Y. Clinical research of Sanhuang Yishen Granule on patients diabetic nephropathy in IV stage. Shi Jie Zhong Yi Yao 2015;10(6):845-8.
Zhao JX. Standardization of diagnosis and treatment in diabetic nephropathy and it's research. Yao Pin Ping Jia 2012;9:31-40.
Li Y, Fan C, Wang HY, Song HP. Effects of Buyanghuanwu decoction (BHD) on TGF-β1 in early diabetic nephropathy. Zhong Guo Yi Yao Dao Bao 2011;13:656-7.
Peng T, Peng L, Teng QM, Liu L, Luo JP, Li ZY, et al
. Zishenhuoxuefang invigorate the party for diabetic nephropathy stage III Qi and Yin deficiency and blood stasis patients blood rheology of clinical observation. Yun Nan Zhong Yi Xue Yuan Xue Bao 2013;36:74-7.
Gao YH, Ma JH, Li YK, Wang YF. Effects on treatment of Tonify Qi of kidney, disperse blood stasis and dredge collateral, clear heat and purging tuybidity on diabetic nephropath serum creatinine. Zhong Guo Yi Yao Xian Dai Yuan Cheng Jiao Yu 2015;13:5-6.
Du YX, Chen L, Ding YJ, Gao HL, Yu MY. Clinical observation on Jinlida granule combined with Tongxinluo capsule in treating diabetic nephropathy. Yi Nan Bing Za Zhi 2012;11:425-7.
Feng R. Clinical Study on Treatment of Early Diabetic Kidney Disease with Sanhuang Yishen Granule. China National Knowledge Infrastructure: The First Clinical Medical School, Beijing University of Chinese Medicine; 2015.
Li YK, Gao YH, Ma JH, Wang YF. 36 cases of diabetic kidney disease treated by the resolving stasis, freeing the collateral vessels, clearing heat and discharging turbidity method. Zhong Guo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu 2014;12:35-7.
Li Y. Clinical and Experimental Study on Diabetic Nephropathy with the Method of Tonify Qi and Yin and Activate Blood and Remove Stasis. Jinan: Shandong University of Traditional Chinese Medicine; 2013.
Liu LC, Liu X, Feng MJ, Zhang YT, Du XF. Influence of Zhuang Shen Gu Jing Fang on diabetic nephropathy at stage III. Xi Bu Zhong Yi Yao 2012;25:11-2.
Shi JB, Huang BY, Zheng RP, Liu F, Cai YQ. 40 cases of early stage diabetic kidney disease of qi and yin deficiency with stasis pattern treated by Shen Qi Dan Tang Shen Xiao decoction. Fu Jian Zhong Yi Yao 2014;45:13-7.
Song SW, Zeng Q, Wu XM. Clinical study of diabetic kidney disease treated by the method of warming kidney, resolving turbidity, expelling stasis and freeing collateral vessels. Shanxi Zhong Yi 2017;38:47-8.
Tong J, Zhou C, Li XZ, Shan YQ, Gao CS. Clinical observation on treatment of diabetic nephropathy with Tangshenkang capsule. Hebei Zhong Yi 1999;21:265-6.
Wang D. The Researches of on the Protective Effect of Shenbaining Water Pill to Incitiant Diabetic Nephropathy. Haerbing: Heilongjiang University of Chinese Medicine; 2005.
Wang YC. Clinical Study on Treatment of Diabetic Kidney Disease with Kidney Deficiency and Blood Stasis Syndrome by Bushen Huayu Decoction. Nanjing: Nanjing University of Traditional Chinese Medicine; 2005.
Wang YN. The Exploration of Inflammatory Injury Mechanism of Tangshenqing NO. 2 in Inhibiting Diabetic Nephropathy and the Assessment of its Clinical Curative Effect. Beijing: Beijing University of Chinese Medicine; 2016.
Wang ZP, Liu LP, Wang YL, Ma Y. Observation on curative effect of Tangshen decoction in treating early stage diabetic kidney disease. Zhong Guo Zhong Yi Ji Zheng 2008;17:466-7.
Xiao R. Clinical Study on Treatment of Early Diabetic Nephropathy with the Method Fo Yi Qi Yang Xue Tong Luo Xiaoji. Jinan: Shandong University of Traditional Chinese Medicine; 2014.
Yang H. The Clinical Trail of Diabetic Kidney Disease with Supplementing Qi, Nourishing Yin and Obstructing the Collaterals Syndrome Treated by Yi Qi Yang Yin Xiao Zheng Tong Luo Decoction. Shijiazhuang: Heibei Medical University; 2014.
Zhang B, Qin BY. Treatment of early diabetic nephropathy with Jisheng Shenqi Pill combined with compound sueshuantong capsule. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2012;18:316-7.
Zhang JH, Li WQ, Geng JG, Du YQ, Miao L, Xing ZH, et al
. Observation of clinical efficacy of modified Xiaokekang for diabetic nephropathy. Beijing Zhong Yi Yao 2015;34:6-9.
Zhang S. The Clinical Observation of Early Stage (III stage) Diabetic Kidney Disease (kidney yin deficiency and binding of stasis and turbidity syndrome) treated by Yi Shen Hua Zhuo decoction. Changchun: Changchun University of Traditional Chinese Medicine; 2010.
Zhao HB, Liang Q, Xu PF. Clinical observation on diabetic kidney disease treated by Su Tang Yi Shen Pill. Xian Dai Zhong Xi Yi Jie He Za Zhi 2008;17:3600-1.
Zhao JX, Mu X, Wang SD, Song ML, Huang XM, Yu XC, et al
. Clinical observation on 31 cases of diabetic nephropathy with renal insufficiency at compensatory phase treated with Zhixiao Wenshenning granule. Zhong Yi Za Zhi 2005;46:677-9.
Zhou H, Shang XZ, Xie PF, Guan S, Sheng T, Yi WM, et al
. Clinical research of replenishing Qi, nourishing Yin, detoxication dredging collateral in treating early diabetic nephropathy. Tianjin Zhong Yi Yao 2009;26:100-2.
Zhao L. Clinical Research on the Treatment of Diabetic Kidney Disease Based on Different Syndrome. Shijiazhuang: Hebei Medical School; 2010.
Wang H, Mu W, Zhai J, Xing D, Miao S, Wang J, et al.
The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: Study protocol for a randomized, double-blind and placebo-controlled clinical trial. Trials 2013;14:165.
Wang Y, Xu A. Zheng: A systems biology approach to diagnosis and treatments. Science, 346(6216):S13-S15.
Hunt LP, Short CD, Mallick NP. Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int 1988;34:382-8.
Viana LV, Gross JL, Camargo JL, Zelmanovitz T, da Costa Rocha EP, Azevedo MJ, et al.
Prediction of cardiovascular events, diabetic nephropathy, and mortality by albumin concentration in a spot urine sample in patients with type 2 diabetes. J Diabetes Complications 2012;26:407-12.
Lind-Ayres M, Thomas W, Holme B, Mauer M, Caramori ML, Moran A, et al.
Microalbuminuria in patients with cystic fibrosis. Diabetes Care 2011;34:1526-8.
Kimura S, Inoguchi T, Yokomizo H, Maeda Y, Sonoda N, Takayanagi R, et al.
Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes Obes Metab 2012;14:666-9.
Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 2006;17:339-52.
Xiao Y, Liu Y, Yu K, Zhou L, Bi J, Cheng J, et al.
The effect of Chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: A systematic review and meta-analysis. Evid Based Complement Alternat Med 2013;2013:937549.
Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al.
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-7.
Kodner C. Nephrotic syndrome in adults: Diagnosis and management. Am Fam Physician 2009;80:1129-34.
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al.
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 2003;63:1499-507.
Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, et al.
Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points. Semin Nephrol 2004;24:147-57.
Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, et al.
Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL study. Kidney Int Suppl 2002;(82):S64-7.
Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al.
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis. Lancet 2015;385:2047-56.
Tu X, Ye X, Xie C, Chen J, Wang F, Zhong S, et al.
Combination therapy with Chinese medicine and ACEI/ARB for the management of diabetic nephropathy: The promise in research fragments. Curr Vasc Pharmacol 2015;13:526-39.
Huang Y, Haaijer-Ruskamp FM, Voorham J. Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes. J Comp Eff Res 2016;5:229-37.
Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, et al.
Efficacy and safety of Tangshen formula on patients with type 2 diabetic kidney disease: A multicenter double-blinded randomized placebo-controlled trial. PLoS One 2015;10:e0126027.
Burgess E. Slowing the progression of kidney disease in patients with diabetes. J Am Soc Hypertens 2008;2:S30-7.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]